Published in Blood on June 01, 1984
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest (1994) 1.23
The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. Biochem J (1989) 1.08
Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake. J Biol Chem (2013) 1.01
Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells. Haematologica (2009) 0.94
Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J (1989) 0.94
Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen. J Clin Invest (1984) 0.94
The roles of protein kinase C and intracellular Ca2+ in the secretion of von Willebrand factor from human vascular endothelial cells. Biochem J (1992) 0.93
Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest (1988) 0.89
Hyaluronic acid accumulation and endothelial cell detachment in intimal thickening of the vessel wall. The normal and genetically defective ductus arteriosus. Am J Pathol (1988) 0.88
Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII. J Biol Chem (2012) 0.86
Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest (1994) 0.85
The Epac-Rap1 signaling pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells. J Biol Chem (2012) 0.84
Differential regulation of von Willebrand factor exocytosis and prostacyclin synthesis in electropermeabilized endothelial cell monolayers. Biochem J (1995) 0.84
Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood (2014) 0.83
The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor. Biochem J (1991) 0.83
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains. J Clin Invest (1993) 0.80
Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa. Biochem J (1995) 0.78
Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII. J Biol Chem (2012) 0.78
Protein tyrosine kinases regulate agonist-stimulated prostacyclin release but not von Willebrand factor secretion from human umbilical vein endothelial cells. Biochem J (1996) 0.78
von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII. Haematologica (2015) 0.77
Platelet-independent adhesion of calcium-loaded erythrocytes to von Willebrand factor. PLoS One (2017) 0.75
Sphingosine-1-phosphate receptor 3 mediates sphingosine-1-phosphate induced release of weibel-palade bodies from endothelial cells. PLoS One (2014) 0.75
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus (2003) 3.61
Cervical lymph node metastasis: assessment of radiologic criteria. Radiology (1990) 3.24
Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature (1979) 3.06
Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost (2007) 2.86
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A (1983) 2.20
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus (1996) 2.14
Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell (1988) 2.13
Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood (2000) 2.12
Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol (1999) 2.06
MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J (1998) 2.05
Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer (1995) 2.00
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
The life cycle of coagulation factor VIII in view of its structure and function. Blood (1998) 1.91
Antimicrobial peptides: properties and applicability. Biol Chem (2001) 1.89
Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood (1998) 1.88
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost (1996) 1.88
Regional localization of the genes coding for human ACO2, ARSA, and NAGA on chromosome 22. Cytogenet Cell Genet (1980) 1.88
The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem (1999) 1.87
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res (2001) 1.86
A mouse model for the cystic fibrosis delta F508 mutation. EMBO J (1995) 1.82
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J (1986) 1.78
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost (2006) 1.68
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Isolation of IIIGlc of the phosphoenolpyruvate-dependent glucose phosphotransferase system of Salmonella typhimurium. J Bacteriol (1981) 1.63
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood (1999) 1.62
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost (2006) 1.59
Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J (1999) 1.58
Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis (1989) 1.57
Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost (2009) 1.56
Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem J (1997) 1.54
Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation (1999) 1.54
Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 1.54
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Biochemical composition of human saliva in relation to other mucosal fluids. Crit Rev Oral Biol Med (1995) 1.53
Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol (1990) 1.53
Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice. Eur Respir J (2010) 1.51
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology (2006) 1.51
Concordance of phenprocoumon dosage in married couples. BMJ (1997) 1.51
Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol (1997) 1.46
Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3? J Thromb Haemost (2007) 1.46
Vascular endothelial cells synthesize a plasma membrane protein indistinguishable from the platelet membrane glycoprotein IIa. J Biol Chem (1985) 1.46
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells. Biochim Biophys Acta (1983) 1.45
Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation (2000) 1.45
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med (1983) 1.44
Phosphoenolpyruvate:sugar phosphotransferase system-mediated regulation of carbohydrate metabolism in Salmonella typhimurium. J Bacteriol (1982) 1.42
A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest (1996) 1.42
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med (1994) 1.40
Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome. Arthritis Rheum (2004) 1.40
Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest (1985) 1.40
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase]. Ned Tijdschr Geneeskd (1990) 1.39
The role of collagen in thrombosis and hemostasis. J Thromb Haemost (2004) 1.38
[Diagnosis of lymph node metastasis of head-neck carcinomas]. Ned Tijdschr Geneeskd (1995) 1.38
Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol (1993) 1.37
Neutrophil and monocyte adherence to and migration across monolayers of cytokine-activated endothelial cells: the contribution of CD18, ELAM-1, and VLA-4. Blood (1991) 1.37
Competition between two pathways for sugar uptake by the phosphoenolpyruvate-dependent sugar phosphotransferase system in Salmonella typhimurium. Eur J Biochem (1981) 1.34
Characterization of factor IIIGLc in catabolite repression-resistant (crr) mutants of Salmonella typhimurium. J Bacteriol (1982) 1.34
Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol (1991) 1.34
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
Purification of human antihemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta (1970) 1.32
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem (1991) 1.32
The hemostatic plug. Semin Hematol (1977) 1.31
Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun (1998) 1.30
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med (1981) 1.29
Nucleotide sequence of the cDNA coding for human complement C1r. Biochemistry (1986) 1.29
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis (2008) 1.28
Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol (1992) 1.28
Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids. J Virol (2001) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26